{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:15:36Z","timestamp":1762431336748,"version":"3.37.3"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2016R1D1A1B03935289"],"award-info":[{"award-number":["2016R1D1A1B03935289"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.dld.2017.10.002","type":"journal-article","created":{"date-parts":[[2017,10,28]],"date-time":"2017-10-28T13:45:57Z","timestamp":1509198357000},"page":"163-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5472-4731","authenticated-orcid":false,"given":"Jung Gil","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Rim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heon Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Young","family":"Tak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Oh","family":"Kweon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Young","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Min","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Seok","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keun","family":"Hur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Kyu","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2017.10.002_bib0005","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.dld.2017.10.002_bib0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age\u2013sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2017.10.002_bib0015","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","author":"Liaw","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2017.10.002_bib0020","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/gast.2001.22461","article-title":"Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease","volume":"120","author":"Perrillo","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.10.002_bib0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dld.2017.10.002_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2017.10.002_bib0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association For The Study Of The Liver","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2017.10.002_bib0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3350\/cmh.2016.22.1.18","article-title":"KASL clinical practice guidelines: management of chronic hepatitis B","volume":"22","author":"The Korean Association for the Study of the Liver","year":"2016","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.dld.2017.10.002_bib0045","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2010.06.043","article-title":"Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B","volume":"54","author":"Wong","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2017.10.002_bib0050","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jhep.2014.02.013","article-title":"Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation","volume":"60","author":"Chen","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2017.10.002_bib0055","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.24109","article-title":"Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure","volume":"53","author":"Garg","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2017.10.002_bib0060","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/135965350601100404","article-title":"Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B","volume":"11","author":"Chan","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1016\/j.dld.2017.10.002_bib0065","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/135965350801300407","article-title":"Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B","volume":"13","author":"Wong","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.dld.2017.10.002_bib0070","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000080877","article-title":"Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection","volume":"47","author":"Tsubota","year":"2004","journal-title":"Intervirology"},{"key":"10.1016\/j.dld.2017.10.002_bib0075","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2017.10.002_bib0080","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2017.10.002_bib0085","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/AAC.02400-13","article-title":"Early entecavir treatment for chronic hepatitis B with severe acute exacerbation","volume":"58","author":"Tsai","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dld.2017.10.002_bib0090","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/AAC.00261-15","article-title":"Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation","volume":"59","author":"Hung","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dld.2017.10.002_bib0095","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","article-title":"Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B","volume":"33","author":"Gish","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.10.002_bib0100","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0168-8278(02)00419-1","article-title":"The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B","volume":"38","author":"Chien","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2017.10.002_bib0105","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1440-1746.2009.06089.x","article-title":"Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure","volume":"25","author":"Sun","year":"2010","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865817312537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865817312537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T20:18:28Z","timestamp":1657916308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865817312537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1590865817312537"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2017.10.002","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2017.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}